The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.

Boye, Kristina S; Mody, Reema; Lage, Maureen J; Malik, Raleigh E

Boye, Kristina S; Mody, Reema; Lage, Maureen J; Malik, Raleigh E.

Affiliation

Boye KS; Eli Lilly and Company, Indianapolis, IN, USA.
Mody R; Eli Lilly and Company, Indianapolis, IN, USA.
Lage MJ; HealthMetrics Outcomes Research, Bonita Springs, FL, USA. Electronic address: lagemj@hlthmetrics.com.
Malik RE; Eli Lilly and Company, Indianapolis, IN, USA.

Clin Ther ; 42(9): 1812-1817.e2, 2020 09.

Article in En | MEDLINE | ID: mdl-32741645

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide-1 Receptor/agonists; Glycated Hemoglobin/analysis; Databases, Factual; Female; Humans; Hypoglycemic Agents/therapeutic use; Male; Middle Aged; Retrospective Studies

Key words

HbA(1c); glucagon-like peptide-1 receptor agonist; time to initiation; type 2 diabetes mellitus

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glycated Hemoglobin / Diabetes Mellitus, Type 2 / Glucagon-Like Peptide-1 Receptor Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2020 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google